<DOC>
	<DOCNO>NCT00063427</DOCNO>
	<brief_summary>Assess clinical activity MAC-321 administer IV second-line third-line antineoplastic agent subject advance colorectal cancer . Clinical activity assess determine percentage subject exhibit objective response ( complete plus partial response ) . Tumor response assess follow modify Response Evaluation Criteria Solid Tumors ( RECIST ) guideline .</brief_summary>
	<brief_title>Study Evaluating MAC-321 Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>Histologic and/or cytologic diagnosis metastatic relapse colorectal cancer time disease candidate surgical resection . Prior treatment least 1 conventional approve therapeutic regimen . Subjects fail prior cytotoxic chemotherapy regimens contain irinotecan ( CPT11 ) , 5 fluorouracil ( 5FU ) , and/or oxaliplatin advance ( relapse ) metastatic colon cancer eligible Other chemotherapy , radiotherapy , immunotherapy , investigational agent within 4 week sign ICF ( 6 week previous chemotherapy include nitrosoureas mitomycin ) Prior radiotherapy &gt; 25 % bone marrow Prior exposure MAC321</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Colorectal Carcinoma</keyword>
	<keyword>Colorectal Tumors</keyword>
	<keyword>Neoplasms , Colorectal</keyword>
	<keyword>Colorectal Neoplasms</keyword>
</DOC>